[Effect of melatonin administration on cyclooxygenase-2 activity, serum levels of nitric oxide metabolites, lipoperoxides and glutathione peroxidase activity in patients with Parkinson’s disease].

What Was Tested

Researchers studied Glutathione in the context of parkinson's disease in this randomized controlled trial publication.

To determine the effect of melatonin (MEL) administration on ciclooxigenase 2 (COX-2) activity and serum concentration of nitric oxide metabolites, lipoperoxides and glutathione peroxidase (GPx) activity in patients with Parkinson's disease.

Who Took Part

According to the abstract, 13 patients were involved.

Patients were assessed using the Unified Parkinson's Disease Scale.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and pilot study.

Random assignment meant chance, not the researchers, decided who got Glutathione and who got the comparison, which limits bias.

Neither the patients nor the staff measuring them knew who was on Glutathione, so expectations could not easily colour the readings.

Some patients received a placebo instead of Glutathione, giving a reference point.

It is described as a pilot, a small early test of whether a larger Glutathione study would be practical.

A blood sample was taken at baseline and every 3 months until 12 months.

What Was Measured

PubMed files the paper under topics including Antioxidants, Cyclooxygenase 2, Glutathione Peroxidase, Lipid Peroxides, Melatonin, Nitric Oxide and Oxidative Stress.

Author keywords: 4-OH-alkenes, Ciclooxigenase 2, Malon-dialdehyde, Nitrates/nitrites and Parkinson.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glutathione in 13 patients in people with parkinson's disease.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 1 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2017 (Gaceta medica de Mexico), a journal based in Mexico.

More context: the Glutathione compound page, Parkinson's disease research.